Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.

Hello,
While we wait to hear more about the results of the presidential election, here’s the latest in healthcare news.
Today: Good news for Biogen’s experimental Alzheimer’s drug, why massive health insurers like UnitedHealth Group are surging, and the US surpasses 103,000 daily COVID-19 cases, the highest single-day count since the pandemic began.

Atthapon Raksthaput / Shutterstock

Biogen just gained $16 billion in market value, as investors increasingly expect approval of the first Alzheimer’s drug in over 15 years. Here’s what comes next.
- What could be the first disease-modifying Alzheimer’s drug got a step closer to US approval on Wednesday.
- The US Food and Drug Administration released crucial documents Wednesday summarizing the evidence for and against Biogen’s experimental treatment called aducanumab.
- The FDA documents stated Biogen has “provided substantial evidence of effectiveness to support approval.”
- The agency is aiming to make a decision on aducanumab by March 7, 2021 at the latest.
Read the full story from Andrew Dunn here>>

Getty

Massive healthcare companies like UnitedHealth Group and Anthem are soaring in the wake of an undecided election — and it's because an overhaul of health insurance is looking less likely
- Health insurance stocks like Cigna and UnitedHealth Group soared on Wednesday morning, even though the 2020 presidential election remains undecided.
- Analysts said it's clear from the election results so far that big healthcare policy changes are unlikely over the next four years.
- The "Blue Wave" failed to materialize, which one analyst said is an "excellent" results for health insurers.
Read the full story from Shelby Livingston here>>

Brittany Murray/MediaNews Group/Long Beach Press-Telegram via Getty Images
The US surpassed 103,000 new daily COVID-19 cases, the highest single-day count in the entire pandemic. And the deadliest wave is yet to come.
- The US reportedly surpassed 103,000 COVID-19 new daily infections on Wednesday, the COVID-19 Tracking Project reported.
- Experts have warned the US is entering the "deadliest" wave of the pandemic as cold weather sets in and people begin hunkering down indoors.
- Close to 9.5 million Americans have already been infected with COVID-19 and over 233,650 have died.
Read the full story from Sarah Al-Arshani here>>
More stories we're reading:
- Oregon voted to legalize the sale of psychedelic mushrooms (Business Insider)
- Gilead is suing health clinics in Florida for alleged HIV drug program fraud (Bloomberg Law)
- There's a 'small chance' Oxford University's COVID-19 vaccine will be ready this year, according to the director of its clinical trial (Business Insider)
- Abbott sued a former executive for allegedly trying to take COVID-19 testing secrets to a rival company (Stat News)
Subscribe to our newsletter here!
- Lydia